

PRESS RELEASE

For Immediate Release

PsychoGenics Appoints Rusiko Bourtchouladze, Ph.D. as Vice President, Cognition and Discovery Research

TARRYTOWN, N.Y., October 4, 2006 – PsychoGenics Inc., announced the appointment of Rusiko Bourtchouladze, Ph.D., as Vice President, Cognition and Discovery Research. This appointment reflects the company's expansion and commitment to cognition and drug discovery.

Dr. Bourtchouladze has over 30 years of experience in developing behavioral models in cognition and memory. Dr. Bourtchouladze is one of the pioneers of modern mouse behavioral genetic research in the US. She has published several landmark papers on the role of cAMP-signaling pathways and CREB in cognition, and mouse models of human cognitive disorders. She is also the author of the scientific popular book *Memories Are Made of This* (Orion Publishing, UK 2002; Columbia Press, USA, 2002; 2004).

“We are delighted that Rusiko has agreed to join the company. She is considered by many a luminary in the field of cognition and she will play an active role in many of our existing partnerships and in-house drug discovery programs.” explained Dr. Emer Leahy, President and CEO. “Her expertise will also be a great asset to our service business as we continue to expand our portfolio of behavior tests.”

Prior to this appointment, Dr. Bourtchouladze held Senior Scientist positions with Dr. Alcino Silva at Cold Spring Harbor Laboratory, New York and Dr. Eric Kandel, at Columbia University, New York. Dr. Bourtchouladze was an Adjunct Associate Professor at Cold Spring Harbor Laboratory and Director of Model Systems at Helicon Therapeutics Inc., NY, since 2001, where she was responsible for the establishment of preclinical models of cognitive function and dysfunction and finding novel targets and drug candidates for memory and cognition.

About PsychoGenics:

PsychoGenics is a leader in preclinical behavioral neurobiology and a provider of customized and innovative solutions for central nervous system (CNS) drug discovery. PsychoGenics works with pharmaceutical and biotechnology companies, academic institutions and not-for-profit research foundations to address such major neurological disorders as: ALS, Huntington's Disease, anxiety, cognitive impairment, depression, psychosis/schizophrenia and SMA. PsychoGenics supports the understanding and treatment of CNS disorders by offering an extensive range of established and customized solutions, including validated *in vivo* behavioral tests, genotyping, behavioral pharmacology, phenotyping, bioinformatics, microdialysis and radiotelemetry.

For more information on PsychoGenics Inc. and its services contact:

David Pushett, Ph.D.

V.P., Business Development

Ph: (914) 593-0640

david.pushett@psychogenics.com

or visit www.psychogenics.com